What Factors Affect a Sufficient Fenofibrate Dose?

Fenofibrate tablets, this product is used to treat hyperlipidemia with unsatisfactory diet control therapy in adults. Its triglyceride lowering and mixed hyperlipidemia effects are more obvious than cholesterol effects.

Drug Name: Fenofibrate
Drug type: Occupational injury medical insurance

Hanyu Pinyin: Fei Nuo Bei Te Pian
Use classification: Lipid-lowering drugs

Fenofibrate ingredients

The main ingredients of this product are: fenofibrate Chemical name: 2-methyl-2- [4- [4-chlorobenzoyl] phenoxy] isopropyl propionate Chemical structural formula:

Molecular formula: C ₂₀ H ₂₁ CLO ₄
Molecular weight: 360.84

Fenofibrate traits

This product is white or off-white film.

Fenofibrate indications

This product is used to treat hyperlipidemia with unsatisfactory effect of diet control therapy in adults. Its triglyceride lowering and mixed hyperlipidemia effects are more obvious than cholesterol effects.

Fenofibrate specifications

0.1g

Fenofibrate dosage and dosage

Adults usually take orally, 0.1g once a day, 3 times a day, and the maintenance amount is 0.1g each time, 1 or 2 times a day.
In order to reduce stomach upset, it can be taken with diet; renal insufficiency and medication for elderly patients should be reduced; discontinuation of treatment after 2 months without effect.

Fenofibrate adverse reactions

The incidence is about 2% to 15%.
Gastrointestinal reactions including abdominal discomfort, diarrhea, and constipation are the most common (about 5%); rash (2%);
Adverse reactions of the nervous system include fatigue, headache, loss of libido, impotence, dizziness, and insomnia (about 3% to 4%);
This product is a chlorobutyric acid derivative, which may cause myositis, myopathy, and rhabdomyolysis syndrome, leading to an increase in blood creatine phosphokinase; rhabdomyolysis, which is mainly manifested as myalgia with increased blood creatine phosphokinase , Myoglobinuria, and can cause renal failure, but it is rare; in patients with nephrotic syndrome and other kidney damage leading to decreased albumin or patients with hyperthyroidism, the risk of myopathy increases. (About 1%);
There is a tendency to increase gallstones, which can cause gallbladder disease and even require surgery;
It can cause mild to moderate hematological changes in the early stage of treatment, such as hemoglobin, hematocrit, and reduction of white blood cells.
Occasionally elevated blood aminotransferases include alanine and aspartate aminotransferases.

Fenofibrate taboos

Disable allergic to fenofibrate;
Patients with a history of gallbladder disease and cholelithiasis are contraindicated. This product can increase the excretion of cholesterol to bile, which can cause gallstones.
Patients with severe renal insufficiency, liver dysfunction, primary biliary cirrhosis, or unexplained persistent abnormal liver function are contraindicated.

Fenofibrate precautions

This product interferes with the diagnosis. When taking this product, platelet count, blood urea nitrogen, aminotransferase, and calcium may increase; blood alkaline phosphatase, -glutamyl transpeptidase, and bilirubin may decrease.
During the medication should be checked regularly:
1. Whole blood and platelet count;
2. Liver function test;
3. Blood cholesterol, triglycerides or low-density lipoproteins;
4. Blood creatine phosphokinase.
If there are clinical symptoms of suspicious myopathy (such as myalgia, tenderness, fatigue, etc.) or a significant increase in blood creatine phosphokinase, the drug should be discontinued.
In the treatment of hyperlipidemia, attention and treatment of various primary diseases that can cause hyperlipidemia, such as hypothyroidism and diabetes, are also needed.
Certain drugs can also cause hyperlipidemia, such as estrogen, thiazide diuretics, and beta-blockers. After discontinuation, corresponding antihyperlipidemic treatment is no longer needed.
Diet therapy is always the first method to treat hyperlipidemia, plus exercise and weight loss methods will be superior to any form of medication.

Fenofibrate tablets for pregnant and lactating women

Banned for pregnant and lactating women. This product has no experimental data for human use.

Fenofibrate tablets for children

The efficacy and safety of this product for children are not confirmed by experimental studies, so this product cannot be used for children.

Fenofibrate tablets for elderly

The clearance rate of single-dose oral administration of this product in the elderly is similar to that of adults, but if renal function is poor, the dosage of this product should be appropriately reduced.

Fenofibrate tablets drug interactions

This product has the effect of enhancing the curative effect of coumarin anticoagulants. At the same time, the prothrombin time can be prolonged. Therefore, the dose of oral anticoagulants should be reduced when combined, and the dosage should be adjusted later according to the test results.
This product is combined with bile acid binding resins, such as cholestyramine, etc., and you should take fenofibrate at least 1 hour or 4-6 hours before taking these drugs. Because bile acid binding drugs can also be combined with other drugs taken at the same time, and then affect the absorption of other drugs.
This product should be used in combination with HMG-C0A reductase inhibitors such as pravastatin, fluvastatin, simvastatin, etc., which can cause myalgia, rhabdomyolysis, blood creatine phosphate kinase increase, and other myopathy. Withdrawal.
This product is mainly excreted by the kidney. When combined with immunosuppressive agents such as cyclosporine or other nephrotoxic drugs, there may be a risk of worsening renal function, which should be reduced or discontinued.
When this product is combined with other prion protein binding rate drugs, they can increase their free form and enhance their efficacy, such as tolbutamide and other sulfonylurea hypoglycemic agents, phenytoin, furosemide, etc. During the taking of the above drugs, the dose of hypoglycemic drugs and other drugs should be adjusted.

Fenofibrate overdose

Because fenofibrate is highly bound to plasma proteins, systemic supportive therapies should be taken when hemodialysis is not considered when the drug is overdose.

Fenofibrate tablets pharmacology and toxicology

This product is a blood lipid regulating drug of chlorobutyric acid derivative. It can reduce blood low density lipoprotein, cholesterol and triglyceride by inhibiting the production of very low density lipoprotein and triglyceride and increasing its catabolism. Apolipoprotein A ₁ and A ₁₁ production increases, thereby increasing high density lipoprotein. This product also has the function of reducing blood uric acid in normal people and patients with hyperuricemia. Animal experiments show that fenofibrate is teratogenic and carcinogenic.

Pharmacokinetics of fenofibrate tablets

After oral administration, the gastrointestinal tract is well absorbed. Taking it with food can increase the absorption of fenofibrate. The blood concentration reached a peak about 4-7 hours after oral administration. The single-dose oral half-life and half-life were 4.9 hours and 26.6 hours, respectively, and the apparent volume of distribution was 0.9 L / kg. The half-life after continuous treatment was 21.7 hours. The plasma protein binding rate was approximately 99%, and no accumulation was found after multiple dose administration. After absorption, it is distributed in liver, kidney, and intestine, followed by lung, heart, and adrenal gland, and there is a small amount in testis, spleen, and skin. Metabolized in liver and kidney tissues, reduced by carboxyl groups and glucuronidation, the majority of metabolites are glucuronidation products, and radiolabeled, about 60% of metabolites are excreted by the kidneys, 25% are metabolized The product is excreted in the stool. The elimination half-life of this product is 20 hours, so it can be administered once a day.
Studies have shown that patients with severe renal insufficiency have significantly reduced the clearance of this product, and long-term medication can cause accumulation.

Fenofibrate tablets storage

Shaded and sealed.

Fenofibrate tablets packaging

High-density polyethylene medicinal plastic bottle packaging, 100 pieces bottle, aluminum plastic packaging, 12 pieces / board.

Fenofibrate

36 months

Fenofibrate film implementation standards

"Chinese Pharmacopoeia" 2005 edition two

^[1]